Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of CC-220 in Healthy Subjects
NCT02034773Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- May 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM) (8 arms), sponsored by Celgene Corporation. Primary endpoint: Adverse Events up to 7 months. Started May 2013; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02034773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034773.